

Long-acting amylin analog studied for satiety signaling. Also stocked as an 8.4:7mg co-formulation with Semaglutide.
For research use only · not for human consumption
Orders are placed, processed, and shipped by Prime Bio Group. Fresno Peptide Lab does not stock or sell product — we may earn a commission at no extra cost to you.
Cagrilintide modulates appetite through agonistic activity on certain gut hormone receptors, which are pivotal in the neuroendocrine regulation of satiety. By enhancing the physiological response of satiety signals, cagrilintide facilitates a reduction in caloric intake and promotes an early sensation of fullness, aiding in hypophagic behavior.
Weight Reduction Clinically, cagrilintide has shown promise in contributing to significant weight loss in obese subjects. It potentially does this by not only reducing caloric intake but also by modulating energy homeostasis, thereby promoting adiposity reduction. Metabolic Parameter Improvement Cagrilintide may positively impact various metabolic parameters, including glycemic control, lipid profiles, and insulin sensitivity.
These effects are crucial for the management of metabolic syndrome components and can decrease the risk of developing type 2 diabetes mellitus and cardiovascular diseases in obese patients. CAGRILINTIDE COA.
Summary of published preclinical and clinical literature, provided for research context only. Not a claim of efficacy and not medical advice.
Long-acting amylin analog studied for satiety signaling. Also stocked as an 8.4:7mg co-formulation with Semaglutide.
Prime Bio Group supplies Cagrilintide as vial. Available options: 8.4mg vial at $210; 8.4mg:7mg CAGRILINTIDE:SEMAGLUTIDE vial at $300.
Yes. Prime Bio Group is a physician-owned lab and provides a certificate of analysis on every batch. A COA reports identity by mass spectrometry and purity by HPLC — if you are not sure how to read one, our guide on reading a certificate of analysis walks through it line by line.